Allergan Announces Two Clinical Trials of Brazikumab for Crohn’s Disease and Ulcerative Colitis

Allergan Announces Two Clinical Trials of Brazikumab for Crohn’s Disease and Ulcerative Colitis
Allergan recently announced two new clinical trials to the test the efficacy of its investigational therapy, Brazikumab, for treatment of two forms of inflammatory bowel disease. The two clinical trials, INTREPID and EXPEDITION, will evaluate brazikumab therapy in Crohn’s disease and ulcerative colitis, respectively. Disease-specific biomarkers will be monitored to assess the treatment outcome. EXPEDITION is

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *